
Sign up to save your podcasts
Or


Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.
By Nate Geraci4.5
6464 ratings
Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.

521 Listeners

2,170 Listeners

1,999 Listeners

946 Listeners

104 Listeners

289 Listeners

798 Listeners

2,022 Listeners

194 Listeners

2,154 Listeners

935 Listeners

83 Listeners

86 Listeners

113 Listeners

828 Listeners